ProKidney (NASDAQ:PROK) Director Sells $314,193.06 in Stock

Posted by Geri Gentry on Aug 20th, 2026

ProKidney Corp. (NASDAQ:PROK – Get Free Report) Director Brian Jg Pereira sold 229,338 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $1.37, for a total value of $314,193.06. Following the sale, the director directly owned 445,897 shares of the company’s stock, valued at $610,878.89. This represents a 33.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Brian Jg Pereira also recently made the following trade(s):

On Thursday, August 20th, Brian Jg Pereira sold 222,948 shares of ProKidney stock. The shares were sold at an average price of $1.42, for a total value of $316,586.16.
On Thursday, August 20th, Brian Jg Pereira sold 27,052 shares of ProKidney stock. The stock was sold at an average price of $1.42, for a total value of $38,413.84.
On Wednesday, August 19th, Brian Jg Pereira sold 222,949 shares of ProKidney stock. The stock was sold at an average price of $1.44, for a total value of $321,046.56.
On Wednesday, August 19th, Brian Jg Pereira sold 27,051 shares of ProKidney stock. The shares were sold at an average price of $1.44, for a total value of $38,953.44.
On Tuesday, August 18th, Brian Jg Pereira sold 27,826 shares of ProKidney stock. The shares were sold at an average price of $1.37, for a total value of $38,121.62.

ProKidney Trading Down 4.1%

Shares of ProKidney stock traded down $0.06 during trading on Thursday, reaching $1.42. The company’s stock had a trading volume of 1,828,075 shares, compared to its average volume of 1,027,994. The stock has a 50-day moving average price of $1.67 and a two-hundred day moving average price of $1.85. The stock has a market capitalization of $429.29 million, a P/E ratio of -2.58 and a beta of 1.66. ProKidney Corp. has a one year low of $1.30 and a one year high of $3.48.

ProKidney (NASDAQ:PROK – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The business had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.19 million. As a group, sell-side analysts anticipate that ProKidney Corp. will post -0.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on PROK shares. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of ProKidney in a report on Monday, May 18th. Wall Street Zen downgraded ProKidney from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings raised ProKidney from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

View Our Latest Stock Analysis on ProKidney

Institutional Investors Weigh In On ProKidney

Several hedge funds have recently bought and sold shares of PROK. Artia Global Partners LP bought a new position in shares of ProKidney during the fourth quarter worth $4,118,000. Renaissance Technologies LLC increased its position in shares of ProKidney by 39.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,250,794 shares of the company’s stock valued at $2,239,000 after buying an additional 355,089 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of ProKidney in the 3rd quarter valued at $158,000. Hudson Bay Capital Management LP acquired a new stake in ProKidney during the 4th quarter worth $101,000. Finally, EntryPoint Capital LLC acquired a new stake in ProKidney during the 4th quarter worth $65,000. 51.59% of the stock is currently owned by institutional investors and hedge funds.

ProKidney Company Profile

(Get Free Report)

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.